IP Library Granted Patent US 7,601,515
Granted Patent B2
US 7,601,515 · App. 11/738,582 · Granted Oct 13, 2009

Process of high purity albumin production

Assignee: Novozymes Biopharma UK Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,601,515
App. No.
11/738,582
Granted
Oct 13, 2009
Kind
B2
Abstract

A process is provided for the preparation of albumin from a yeast culture medium which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises separating the yeast from the culture medium to yield an albumin solution; subjecting the albumin solution to positive mode cation exchange, affinity, and positive mode anion exchange chromatography; and concentrating and formulating the albumin with sodium octanoate and sodium chloride.

Claims (15)

1. A process for producing albumin from a yeast culture medium obtained by culturing yeast transformed with an albumin-encoding nucleotide sequence in a fermentation medium and filling a container with the albumin, whereby said yeast expresses and secretes the albumin, the process comprising

(a) separating the yeast from the culture medium to thereby yield an albumin solution;

(b) subjecting the albumin solution to

(1) cation exchange chromatography, wherein albumin is bound to a cation exchange material and then the bound albumin is eluted from the cation exchange material;

(2) affinity chromatography, wherein albumin is bound to an affinity chromatography material comprising an albumin-binding compound and then the bound albumin is eluted from the affinity chromatography material; and

(3) anion exchange chromatography, wherein albumin is bound to an anion exchange material and the albumin is eluted from the anion exchanger material;

(c) concentrating and formulating the albumin with sodium octanoate and sodium chloride; and

(d) filling a container with the albumin obtained from step (c).

2. A process according to claim 1 wherein the albumin is obtained from a yeast culture medium that is fermented at 30° C. at pH 5.7±0.2.

3. A process according to claim 1 wherein said filling of a container with albumin involves filling a vial.

4. A process according to claim 1 wherein, prior to the cation exchange, the albumin is conditioned by adding octanoate thereto to a final concentration of from about 1-10 mM and adjusting the pH to about 4.0-5.0.

5. A process according to claim 1 wherein the yeast is S. cerevisiae.

6. A process according to claim 5 wherein the albumin is obtained from a yeast culture medium that is fermented at 30° C. at pH 5.7±0.2.

7. A process according to claim 1 wherein said separating is performed by centrifugation.

8. A process according to claim 7 wherein the centrifugation is continuous centrifugation.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2011
From: NOVOZYMES BIOPHARMA UK LIMITED
To: NOVOZYMES BIOPHARMA DK A/S
Reel/Frame 026813/0938 →
CHANGE OF NAME Recorded Aug 25, 2011
From: DELTA BIOTECHNOLOGY LIMITED
To: NOVOZYMES BIOPHARMA UK LIMITED
Reel/Frame 026808/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2008
From: SLEEP, DARRELL; VAN URK, HENDRIK; BEREZENKO, STEPHEN; WOODROW, JOHN RODNEY; JOHNSON, RICHARD ALAN; WOOD, PATRICIA CAROL; BURTON, STEPHEN JAMES; QUIRK, ALAN VICTOR
To: DELTA BIOTECHNOLOGY LIMITED
Reel/Frame 021947/0805 →
CHANGE OF NAME Recorded Dec 8, 2008
From: DELTA BIOTECHNOLOGY LIMITED
To: NOVOZYMES DELTA LIMITED
Reel/Frame 021936/0283 →
CHANGE OF NAME Recorded Dec 8, 2008
From: NOVOZYMES DELTA LIMITED
To: NOVOZYMES BIOPHARMA UK LIMITED
Reel/Frame 021940/0682 →
Continuity (5)
Continuation 1087350400 · Jun 22, 2004
Continuation 1030135700 · Nov 21, 2002
Continuation 0895255800 · Feb 24, 1999
Continuation In Part 0837885900 · May 25, 1995
Related Publication 20080009042A1 · Jan 10, 2008